According to FutureWise analysis, the Alcoholic Hepatitis Therapeutics market was estimated to be US$0.92 billion in 2025 and is expected to reach US$1.38 billion by 2033, at a CAGR of 5.2%. The growth of the alcoholic hepatitis therapeutics market is primarily driven by the rising incidence of alcohol use disorders worldwide and a growing awareness of liver diseases among both healthcare professionals and patients. This expansion highlights the urgent need for effective treatment options, as alcoholic hepatitis remains a significant cause of liver-related mortality, with currently limited therapeutic alternatives available in the market.
This growth is fueled by the rising incidence of alcohol-related liver disorders and an increased awareness of the importance of early diagnosis and intervention. Advancements in targeted therapies and the development of biologics are also leading to better treatment outcomes. Furthermore, increased healthcare investments in liver disease management are driving market expansion.
In May 2024, DURECT Corporation received FDA Breakthrough Therapy designation for larsucosterol, indicating its potential in treating alcohol-associated hepatitis.
The FEMTAH trial indicates that fecal microbiota therapy is a safe and effective treatment option for patients who are ineligible for steroids, offering a novel approach.
Alcoholic hepatitis (AH) is liver inflammation caused by drinking alcohol. It is identified by the rapid onset of jaundice, malaise, anorexia, tender hepatomegaly, and systemic inflammatory response syndrome (SIRS) features. Alcoholic hepatitis most likely occurs in individuals who drink heavily over many years. Patients with alcoholic hepatitis are systemically ill with a high risk of nutritional deficiency, acute kidney injury (AKI), infection, and development of multiorgan failure (MOF) syndrome. For instance, approximately two-thirds of the US adult population drinks alcohol each year, and 7.4% report heavy drinking and meet the criteria for alcoholism. However, only a minority of heavy drinkers will develop alcoholic liver disease (ALD), likely due to environmental and genetic factors. To enhance clinical outcomes for patients with severe alcoholic hepatitis, it is crucial to accurately identify possible complications and understand the basic mechanisms underlying alcohol-induced liver damage.
Corticosteroids are the current primary treatment for severe alcoholic hepatitis (defined as DF ≥ 32, MELD ≥ 21, or presence of hepatic encephalopathy) in patients without contraindications for steroid treatment. Corticosteroids alter the balance of cytokines, reducing pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), and increasing anti-inflammatory cytokines, such as interleukin-10. Corticosteroids have potent anti-inflammatory effects. In cases of severe alcoholic hepatitis, there is significant inflammation in the liver. Corticosteroids can help reduce this inflammation, which may help improve liver function. They also have immunosuppressive properties, which can be beneficial in cases where the immune system is overactive and contributes to liver damage.
FutureWise Market Research has published a report that provides insightful trends in the alcoholic hepatitis therapeutics market, affecting overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes the stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the alcoholic hepatitis therapeutics market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.